99 articles - From Friday Aug 01 2025 to Friday Aug 08 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin Gastroenterol Hepatol |
|---|
The EXTENT Study: Results from an International Expert Delphi Consensus to define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn's Disease. Ultrasonographic equivalents for assessing small bowel and colonic damage in CD were derived to align with the validated LI criteria for MRE and colonoscopy. These statements mark the first phase of the EXTENT project, supporting the potential use of IUS in clinical practice and disease modification trials as an alternative tool for bowel damage assessment. The lack of consensus on grade 1 stricturing lesions suggests further exploration of IUS parameters is required. |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Efficacy and Safety of Vedolizumab and Tofacitinib (VETO) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti-TNF and a Second-Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial. VETO was effective and safe in patients with UC refractory to anti-TNF and second-line therapies, with over half achieving clinical remission by 24 weeks. |
Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS. TIPS insertion seems to improve physical functioning, as indicated by a decreasing LFI, but only in patients with a poor performance in LFI prior to TIPS. Conducting LFI prior to elective TIPS insertion can identify those with an excellent prognosis. However, frailty should not be considered a contraindication for TIPS. |
| Am J Gastroenterol |
Refined carbohydrate, different staple foods intake and risk of metabolic dysfunction-associated steatotic liver disease: a prospective community-based cohort study. Higher intake of total refined carbohydrate and rice was positively related with MASLD, and higher intake of wheat, coarse grains and yams might mitigate the risk of MASLD in Chinese population. These results underscored the significance of dietary patterns in preventing MASLD. |
Ultra-Processed Grains and Risk of Inflammatory Bowel Disease: Results from the Prospective Urban Rural Epidemiology (PURE) Study. Higher intake of ultra-processed grains is associated with significantly increased risk of developing IBD. A healthy eating pattern should minimize consumption of ultra-processed grains. Further studies should be performed to understand which components of ultra-processed grains may be detrimental for health. |
| Clin Gastroenterol Hepatol |
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis. Overall, this study demonstrated that oral MORF-057 is well tolerated, with promising efficacy for individuals with moderately to severely active UC. Clinical trial identifier NCT05291689 CLINICAL TRIAL REGISTRY WEBSITE |
Comparative Safety of Janus Kinase inhibitors vs. Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases. In an observational study of patients with IBD, JAK inhibitors were not associated with an increased risk of serious infections, VTE, or MACE compared with TNF antagonists, though the overall risk of infections was higher. |
Diagnostic yield of whole exome sequencing in adult-onset cholestatic liver disease. This study highlights the value of WES in the diagnostic workup of adult-onset cholestatic liver disease and expands our understanding of its genetic landscape, paving the way for larger-scale studies. |
Identifying risk factors for metachronous colorectal cancer in Lynch syndrome. This study identifies important risk factors for metachronous CRC in LS patients, which may support personalized counseling regarding surgical strategies. The findings highlight the complexity of surgical decision-making and the need for individualized approaches. Further studies are required to refine risk stratification and evaluate long-term outcomes to optimize patient care. |
Preoperative body composition parameters are associated with postoperative outcomes in patients with Crohn's disease. Preoperative myosteatosis was consistently associated with overall postoperative complications, moderate-to severe, and infectious complications, in patients with CD following ICR. Furthermore, several body composition parameters were identified as risk factor or protective factor for postoperative complications and ePOR. Inconsistent findings were observed for SM levels and ePOR risk. The correlation between improvements of these parameters and postoperative outcomes requires further study. |
Repeatability and reproducibility of artificial imaging based digital pathology for the evaluation of liver fibrosis. The qFibrosis system has good repeatability and reproducibility for fibrosis staging. It can provide an accurate reference for pathologists to stage liver fibrosis more objectively. |
The Prevalence and Burden of Disorders of Gut-Brain Interaction (DGBI) before versus after the COVID-19 Pandemic. The population prevalence and burden of DGBI have increased following the COVID-19 pandemic. Healthcare services and research funding bodies need to adapt to this post-COVID rise in DGBI and address how to best manage this patient group. |
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study. Consistent with the primary analysis, upadacitinib was more efficacious than placebo in achieving clinical and endoscopic endpoints in patients with Crohn's disease. The safety profile remained consistent with no new safety signals. Number NCT03345823. |
| Endoscopy |
Added value of a balloon-based mucosal exposure device in computer-aided detection-assisted colonoscopy: a randomized controlled trial (COMBAT study). In a FIT-based screening program, adding a balloon-based mucosal exposure device to CADe-assisted colonoscopy did not enhance the detection of subjects with high risk features or of neoplastic lesions. A CADe-related ceiling effect may have limited the benefit of the additional device. |
Cost-effectiveness of colon capsule endoscopy in colorectal cancer screening: a modeling study. However, these increases came at high financial cost, and CCE cost-effectiveness was dominated by biennial FIT and 10-yearly colonoscopy. CCE was not cost effective for CRC screening compared with biennial FIT and 10-yearly colonoscopy. |
Number, depth, and location of inadvertent pancreatic guidewire cannulations and post-ERCP pancreatitis from multi-center real-time intra-procedural data. Single main PD duct canulation is independently associated with PEP and appears to be responsible for most of the magnitude of the association with PD cannulation. These data lend additional support to the use of preventative interventions such as PD stenting in cases where the PD is inadvertently cannulated. |
Topical hemostatic agents in endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review. Topical hemostatic agents offer effective options for managing GI bleeding. Products like Purastat, TC-325 Hemospray, EndoClot PHS, Nexpowder, Ankaferd Blood Stopper, and CG GEL have shown promising results in achieving hemostasis; however, further RCTs and cost-effectiveness analyses are needed to better establish their roles in endoscopic practice. |
| Gastroenterology |
A randomized trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms. DSETAMIS-2018 Study. ESD appears to be non-inferior to TAMIS for local resection of ERNs regarding 12-month recurrence. Both show favorable safety profiles. ESD was associated with fewer technical constraints, higher procedural success, shorter hospitalization, lower cost, and greater patient acceptance. These results should be interpreted considering the wide non-inferiority margin, limited sample size, and absence of multiplicity adjustment. |
GastroNet-5M: A Multicenter Dataset for Developing Foundation Models in Gastrointestinal Endoscopy. This study presents GastroNet-5M, a dataset of roughly 5 million endoscopic images. Pretraining endoscopic deep learning systems with GastroNet-5M improves diagnostic accuracy, reduces the need for scarce application-specific endoscopic imagery and annotations, and increases their robustness to the inevitable data heterogeneity in clinical practice. This may significantly accelerate development and implementation of endoscopic AI systems. GastroNet-5M is publicly available for scientific use. |
Low FODMAP diet improves colonic barrier function and mast cell activation in patients with IBS-D: A mechanistic trial. IBS-D patients exhibited improvement in colonic barrier dysfunction, mast cell recruitment, and activation post-LFD. FODMAP-mediated barrier dysfunction in IBS-D is mediated by direct activation of the TLR4 receptor on colonic mast cells by fecal LPS. (NCT04542018). |
Selective urokinase inhibition plus chemotherapy: A novel approach to pancreatic cancer treatment via enhanced anti-tumour immunity and decreased metastasis. BB2-30F-based uPA-targeted therapy is innovative and effectively curtails local tumour growth and metastasis in PDAC mouse models, suggesting the potential to significantly improve patient outcomes. Our findings highlight the role of uPA in PDAC progression, supporting the targeting of uPA protease activity as a promising therapeutic approach for PDAC. |
| Gut |
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure. These patients are unlikely to achieve spontaneous HBsAg seroclearance, but also have suboptimal responses to novel antivirals. Our data has important implications for novel antiviral development. |
Real-world impact of implementing lumen-apposing metal stents for pancreatic fluid collections: a nationwide Japanese study. The implementation of LAMS was not associated with improved key clinical outcomes but was linked to a higher risk of bleeding and increased healthcare costs. These findings do not support the routine use of LAMS for EUS-guided treatment of al PFCs in standard clinical practice but may restrict it to WON cases with clear indications. |
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential. This study reveals that increased CNNM4 expression drives CCA progression and malignancy and that its inhibition may be an effective therapeutic strategy to limit proliferation and metastasis in patients with CCA. |
Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma. AURKB regulates cholesterol levels and immune microenvironment in tumours, highlighting that targeting AURKB or adopting cholesterol-reducing strategy holds promise for CCA treatment, especially in conjunction with first-line chemoimmunotherapy. |
| Hepatology |
Pilot trials of oral betaine in participants with non-alcoholic fatty liver disease and elevated alanine aminotransferase. Betaine 8 g/d, 4 g/d, and 2 g/d for 12-24 weeks significantly reduced ALT and other serologic markers of liver injury among participants with clinically defined MASLD and an elevated ALT. |
| J Hepatol |
Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease. Overall, we provide a human-based model that captures the epithelial complexity and specific patient features. This approach helps to identify drivers of cell plasticity and expanding organoid-based liver disease modeling for personalized medicine. Impact and implications Here, we describe the generation of biopsy-derived organoids (b-Orgs) from patients with liver disease. b-Orgs capture the liver epithelial cell composition found in patients' liver tissue and are efficiently generated from different stages of the disease, providing a platform for patient-tailored disease modeling and drug testing. |
Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma. Targeting XOR-mediated EGFR stabilization and MUC1 upregulation represents a promising therapeutic strategy to inhibit iCCA progression and enhance sensitivity to EGFR TKIs in patients with iCCA. Impact and implications This study identifies XOR as a key driver of resistance to EGFR tyrosine kinase inhibitors (TKIs) in intrahepatic cholangiocarcinoma (iCCA), addressing a major limitation of current targeted therapies. By promoting EGFR stability through USP8-mediated deubiquitination and MUC1 upregulation, XOR enhances DNA repair and sustains oncogenic signaling. Inhibition of XOR sensitizes iCCA cells to EGFR TKIs, suppresses tumor progression, and exacerbates DNA damage. These findings suggest that targeting XOR could overcome TKI resistance and offer a novel therapeutic strategy for iCCA, potentially improving outcomes in a patient population with limited effective treatment options. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
Effectiveness and Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Immunocompromised Patients. The safety and effectiveness outcomes of FMT in mild to moderately immunocompromised populations for recurrent CDI are comparable to those in immunocompetent cohorts. |
| Gastroenterology |
| Gut |
Spatial single-cell omics: new insights into liver diseases. A recent example in immuno-oncology is the use of spatial architecture-based immune classifications, which can improve patient stratification. In this review, we provide an overview of the current methodology and novel spatial insights into metabolic, infectious, immune-mediated, toxic and malign liver diseases and discuss perspectives for clinical translation. |
| J Hepatol |
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma. We propose that future trials should incorporate hepatic decompensation as a clinically meaningful and prognostically relevant intermediate secondary endpoint to uncouple the competing effects of decompensation and tumour progression on overall survival -the gold standard endpoint for the regulatory approval of systemic HCC therapy. Clinical practice should adopt an integrated a multifaceted treatment approach that addresses both the underlying liver disease and the superimposed cancer disease to optimize overall patients' outcomes throughout the expanding therapeutic landscape. |
Phosphatidylethanol in steatotic liver disease. We highlight its potential to improve both patient care and research in hepatology. Finally, we discuss future directions and current unmet needs which ultimately can move PEth towards broader, evidence-based integration into clinical medicine. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastroenterology |
| Gut |
| Hepatology |
| J Hepatol |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| J Hepatol |